Advances in precision oncology using patient-derived organoids and functional biomaterials
Frontiers in Cell and Developmental Biology · 30.09.2025 · 13
DOI: 10.3389/fcell.2025.1670328 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 30.09.2025. Verfasst von Hina Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, United States. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite major advances in oncology, cancer therapy continues to face persistent challenges due to intratumoral heterogeneity, drug resistance, and the poor clinical translation of experimental therapeutics. Conventional preclinical models such as 2D cultures and animal systems often fail to accurately recapitulate the tumor microenvironment immune contexture, and patient-specific variability limiting their predictive power. While nanomedicine and advanced drug delivery platforms offer promising solutions, their translational success is hindered by insufficient integration with physiologically relevant tumor models. In this review, we critically examine how patient-derived organoids derived from patient tumors serve as next-generation platforms for modeling cancer heterogeneity, therapeutic response, and biomarker discovery. We further explore how the integration of PDOs with functional biomaterials, extracellular matrix mimetics, and organ-on-chip systems enables dynamic co-culture environments that capture tumor–stroma–immune interactions with high fidelity. By linking the biological underpinnings of resistance, such as genetic mutations, altered signaling, metabolic rewiring, and immune evasion, with smart biomaterial design and drug screening workflows, we propose a unified roadmap for precision oncology. Additionally, we highlight the emergence of PDO biobanks, co-culture innovations, and high-throughput phenotypic screening as essential tools for improving clinical translation. This interdisciplinary synthesis underscores the transformative potential of PDO-based platforms in accelerating personalized cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, United States.
- The Novo Nordisk Foundation, Center for Biosustainability, Technical University of Denmark, Kogens Lyngby, Denmark.
- Systems and Synthetic Biology Division, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Zitieren
APA
Singh, H., Mijakovic, I., & Singh, P. (2025). Advances in precision oncology using patient-derived organoids and functional biomaterials. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1670328
Vancouver
Singh H, Mijakovic I, Singh P. Advances in precision oncology using patient-derived organoids and functional biomaterials. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1670328
BibTeX
@article{Singh2025,
author = {Singh, Hina and Mijakovic, Ivan and Singh, Priyanka},
title = {Advances in precision oncology using patient-derived organoids and functional biomaterials},
journal = {Frontiers in Cell and Developmental Biology},
year = {2025},
volume = {13},
doi = {10.3389/fcell.2025.1670328}
}
EUVIMED